Amended Current Report Filing (8-k/a)
February 21 2019 - 5:16PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report
(Date of earliest event reported): March 7, 2017
OncBioMune
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-52218
|
|
20-2590810
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer
Identification No.)
|
11441
Industriplex Blvd, Suite 190.
Baton Rouge, LA
|
|
70809
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(225)
227-2384
Registrant’s
telephone number, including area code
Not
applicable.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [x]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
EXPLANATORY
NOTE
This
amendment on Form 8-K/A (this “Amended Report”) is being filed by OncBioMune Pharmaceuticals, Inc. (the “Company”)
solely to replace incorrect versions of the Contribution Agreement filed as Exhibit 10.1, the Irrevocable Trust Agreement filed
as Exhibit 10.2 and the Shareholders Agreement filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K dated March
13, 2017 (the “Original Filing”) with the correct versions of thereof. The attached Exhibits 10.1, 10.2 and 10.3 supersede
and replace the previously filed Exhibits 10.1, 10.2 and 10.3 in their entirety.
Except
for the foregoing, this Amended Report does not amend, modify or update the Original Filing in any way and should be read in conjunction
with the Original Filing, which speaks only as of its original filing date.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
|
Exhibit
No.
|
|
Description
|
|
10.1
|
|
Contribution Agreement to the Property of Trust F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. dated March 10, 2017.
|
|
|
|
|
|
10.2
|
|
Irrevocable Trust Agreement Number F/2868 entered into among Manuel Cosme Odabachian, Carlos Fernando Alaman Volnie and OncBioMune Pharmaceuticals, Inc. as beneficiaries and Banco Actinver, S.A., as Trustee (“Banco Actinver”) (the “Trust Agreement”) dated March 10, 2017.
|
|
|
|
|
|
10.3
|
|
Shareholders Agreement among OncBioMune Pharmaceuticals, Inc., Jonathan F. Head, Ph.D., Andrew A. Kucharchuk, Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March 10, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
ONCBIOMUNE
PHARMACEUTICALS, INC.
|
|
|
|
|
|
Dated:
February 21, 2019
|
By:
|
/s/
Andrew A. Kucharchuk
|
|
|
Name:
|
Andrew A. Kucharchuk,
|
|
|
Title:
|
President and Chief Financial Officer
|